AbbVie Inc. took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, tax reform is the key to boosting U.S. manufacturing. The ...

An AbbVie research and development lab in San Francisco. (Brian L. Frank for The Wall Street Journal) Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other ...

For the last reported quarter, it was expected that AbbVie would post earnings of $2.13 per share when it actually produced earnings of $2.16, delivering a surprise of +1.41%.

AbbVie Inc. ABBV, a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company's stock traded at ...

AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025. Management will participate in a fireside chat at 12:00 p.m. Central time ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to ...

As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025. It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its ...

Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

AbbVie (ABBV) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a ...